Catalent announced the launch of its cell line development technology, GPEx® Boost. The technology enhances Catalent’s GPEx expression platform through multiple improvements, including utilization of a glutamine synthase (GS) knock-out Chinese hamster ovary (CHO) cell line.
GPEx Boost has been shown to improve titers up to four-fold, potentially to 10 g/L for standard monoclonal antibodies, while maintaining the stability benefits offered by the traditional GPEx platform. In addition, benefits have been observed in cell growth and viability. Developmental timelines for projects can be shortened and made more efficient by combining this new platform with the rapid screening capabilities of Berkeley Lights’ Beacon® optofluidic platform, and ambr® automated micro bioreactors.
“GPEx Boost technology builds on the proven GPEx platform to enable significantly higher productivity and stability for even the most difficult-to-express proteins,” said Michael Riley, President, USA Region of Catalent Biologics. “This new proprietary platform can also be combined with other state-of-the-art technology, such as the Beacon system, to provide a unique development tool for our customers.”
Catalent’s proprietary GPEx technology creates stable, high-yielding mammalian cell lines with high speed and efficiency. The advantages of applying GPEx technology span from early feasibility studies to clinical manufacturing, through to commercial scale production. To date, 12 biopharmaceutical drugs produced using GPEx technology have been approved and marketed, with more than 120 ongoing clinical trials utilizing therapeutic candidates developed using the GPEx platform.